Oncology Institute Inc’s filing revealed that its Director Pacala Mark L unloaded Company’s shares for reported $0.2 million on Nov 18 ’25. In the deal valued at $4.00 per share,50,000 shares were sold. As a result of this transaction, Pacala Mark L now holds 174,971 shares worth roughly $0.55 million.
Then, MARK PACALA bought 50,000 shares, generating $200,000 in total proceeds.
Before that, M33 Growth I L.P. sold 6,018,168 shares. Oncology Institute Inc shares valued at $18,596,139 were divested by the Director at a price of $3.09 per share. As a result of the transaction, M33 Growth I L.P. now holds 7,932,389 shares, worth roughly $24.83 million.
Noble Capital Markets initiated its Oncology Institute Inc [TOI] rating to an Outperform in a research note published on July 23, 2025; the price target was $8. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who began to cover the stock in mid July with a ‘”a Buy”‘ rating. BTIG Research began covering TOI with “Buy” recommendation on May 15, 2025.
Price Performance Review of TOI
On Friday, Oncology Institute Inc [NASDAQ:TOI] saw its stock fall -3.40% to $3.13. Over the last five days, the stock has lost -21.16%. Oncology Institute Inc shares have risen nearly 1638.89% since the year began. Nevertheless, the stocks have risen 912.95% over the past one year. While a 52-week high of $4.88 was reached on 10/24/25, a 52-week low of $0.13 was recorded on 01/10/25.
Levels Of Support And Resistance For TOI Stock
The 24-hour chart illustrates a support level at 3.04, which if violated will result in even more drops to 2.96. On the upside, there is a resistance level at 3.24. A further resistance level may holdings at 3.36.
How much short interest is there in Oncology Institute Inc?
A steep rise in short interest was recorded in Oncology Institute Inc stocks on 2025-10-31, dropping by -0.31 million shares to a total of 4.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 5.1 million shares. There was a decline of -6.49%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 14, 2022 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
